|1.||Kamei, Satoshi: 2 articles (01/2015 - 03/2008)|
|2.||Morita, Akihiko: 2 articles (01/2015 - 03/2008)|
|3.||Olaya, Joffre E: 2 articles (12/2014 - 11/2013)|
|4.||Bennett, Pauleen C: 2 articles (09/2005 - 07/2005)|
|5.||Ong, Ben: 2 articles (09/2005 - 07/2005)|
|6.||Ponsford, Jennie: 2 articles (09/2005 - 07/2005)|
|7.||Mansbach, William E: 1 article (04/2015)|
|8.||Clark, Kristen M: 1 article (04/2015)|
|9.||Mace, Ryan A: 1 article (04/2015)|
|10.||Niu, Xiaoyu: 1 article (01/2015)|
|1.||Substance-Related Disorders (Drug Abuse)
01/01/1990 - "The author describes the development of the research activity at a psychiatric clinic near Oslo, Modum Bads Nervesanatorium, a psychotherpeutic-oriented institution treating patients with neuroses, substance abuse and character disorders. "
06/01/2011 - "Patients in LETS ACT had significantly higher rates of substance abuse treatment retention and significantly greater increases in activation on the Behavioral Activation for Depression Scale (BADS) compared to those in SC. "
|2.||Schizophrenia (Dementia Praecox)
01/01/2014 - "The aim of this study was to explore whether the IFS is as sensitive and specific as the BADS, a battery designed to assess the dysexecutive syndrome, in schizophrenia. "
12/01/2009 - "The purpose of this study was: 1) to examine the feasibility and validity of the Virtual Action Planning-Supermarket (VAP-S) to assess EF in persons with schizophrenia as compared to a standardized EF measure (the Behavioral Assessment of Dysexecutive Syndrome, BADS); 2) to compare performance of persons with schizophrenia and healthy controls in the VAP-S; 3) to assess the ability of the VAP-S to differentiate between different levels of EF within schizophrenia; 4) to explore the relationships between negative and positive symptoms and performance on the tests. "
06/01/2009 - "The purposes of this study were to explore the diagnostic features of the behavioral assessment of the dysexecutive syndrome battery (BADS) in the Spanish population of chronic schizophrenia patients, its concurrent validity with other classic neuropsychologic tests of executive dysfunction, and its correlates with clinical variables. "
04/01/2007 - "The purpose of this study was to establish further the validity of the Behavioural Assessment of the Dysexecutive Syndrome (BADS) in a population with schizophrenia. "
08/01/1999 - "This study investigates performance of patients with schizophrenia on the recently developed Behavourial Assessment of the Dysexecutive Syndrome (BADS). "
|3.||Dystonia (Limb Dystonia)
01/01/2015 - "Dystonia (n = 13 patients) was categorized using the Barry-Albright-Dystonia Scale (BADS). "
12/01/2014 - "Two of the authors independently assessed outcomes using the Barry-Albright Dystonia Scale (BADS) and the Burke-Fahn-Marsden Dystonia Rating Scale-movement (BFMDRS-M). "
04/01/2014 - "Functional evaluation was assessed by the Gross Motor Functional Classification System (GMFCS) and Barry-Albright Dystonia Scale (BADS). "
04/01/2004 - "The Barry-Albright Dystonia Scale (BADS) was used for clinical evaluation of dystonia. "
06/01/2010 - "This study investigated the reliability and validity of the Barry-Albright Dystonia Scale (BADS), the Burke-Fahn-Marsden Movement Scale (BFMMS), and the Unified Dystonia Rating Scale (UDRS) in patients with bilateral dystonic cerebral palsy (CP). "
09/01/2009 - "The purpose of the present study was to determine the sensitivity of the Behavioral Assessment of the Dysexecutive Syndrome (BADS), and to detect early specific signs of the dysexecutive syndrome in the transition from normal cognition to dementia. "
04/01/2015 - "The BADS can be rapidly administered, is sensitive to mood diagnoses in both patients without dementia and with dementia, and produces separate depression and anxiety factor scores that can be used clinically to identify probable mood diagnoses."
01/01/2010 - "Although the psychometric characteristics of BADS have previously been investigated in distinct neurological disorders, data on its validity in Parkinson's Disease (PD) without dementia are still lacking. "
01/01/2011 - "The aim of this study was to compare BADs of young stroke patients without FD to those of FD patients and of healthy age-matched controls. "
06/01/2014 - "However, there was no association between the overall BADS scores and the driving assessment scores of the stroke participants. "
01/01/2011 - "Enlarged BADs were able to detect FD within a cohort of FD, stroke patients and healthy controls. "
01/01/2011 - "FD patients could be significantly separated from stroke patients by BADs (area under the curve = 0.89, 95% confidence interval 0.81-0.98). "
01/01/2011 - "Compared to the non-FD stroke patients, FD patients had significantly enlarged BADs. "
|1.||Tyr sulfate(1)- enkephalinamide-Leu (LETS)
|4.||Hypnotics and Sedatives (Sedatives)
|5.||amsonic acid (DAS)